Trade INBX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Inhibrx Biosciences, Inc. (INBX) is trading at US$109.35, up 4.41% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$1.53B. Over the past 52 weeks, INBX has traded between US$26.20 and US$155.29. On Syfe you can trade INBX with $0 commission and add it to your watchlist.
| Previous close | US$104.73 |
|---|---|
| Market cap | US$1.53B |
| 52-week range | US$26.20 – US$155.29 |
| Volume | 468.39K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Year: 2024
Inhibrx Says INBRX-106 With Pembrolizumab Achieves Higher Response Rate in Phase 2 Trial
May 11, 2:36 PM · MT Newswires
Sector Update: Health Care Stocks Mixed Late Afternoon
Apr 22, 7:59 PM · MT Newswires
Inhibrx Biosciences, Inc. (INBX) stock is trading at US$109.35, +4.41% from the previous close of US$104.73.
The market cap for Inhibrx Biosciences, Inc. (INBX) stock is approximately US$1.53B.
The 52-week high for Inhibrx Biosciences, Inc. (INBX) stock is US$155.29.
The 52-week low for Inhibrx Biosciences, Inc. (INBX) stock is US$26.20.
Inhibrx Biosciences, Inc. (INBX) does not currently pay a dividend.
Stay on top of INBX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
